Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Ventyx Biosciences Inc. Common Stock
VTYX | US
2.39
USD-0.15
-5.91%
VTYX | US
About Ventyx Biosciences Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.39
Open
2.52
High
2.54
Low
2.34
Ventyx Biosciences Inc. a clinical-stage biopharmaceutical company develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958 a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis psoriatic arthritis and Crohn's disease. It is also developing VTX002 a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735 a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition the company develops VTX3232 a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences Inc. was incorporated in 2018 and is based in Encinitas California.
View LessVTYX | US
Risk
69.1
Sharpe
-0.61
Luna's Score
52/100
Recommendation
Hold
Luna says (VTYX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
75.4%1 month
69.1%3 months
80.0%6 months
105.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.62
Debt to equity
0.04
Debt to assets
0.04
Ent. to EBITDA
-22.93
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-185.55M
MarketCap
168.90M
MarketCap(USD)
168.90M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-56.29
Short ratio
5.82
Short perc.
14.19
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.57
Range1M
0.75
Range3M
1.29
Volumes: Market Activity
Rel. volume
0.35
Price X volume
1.33M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -22.93 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.62 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 80.04 | - | Par |
| Debt to Equity | 0.04 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 168.90M | - | Emerging |
